{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:10:40Z","timestamp":1779145840347,"version":"3.51.4"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>PatientInnen mit kardiovaskul\u00e4ren, renalen oder metabolischen Erkrankungen haben ein erh\u00f6htes Risiko f\u00fcr Hyperkali\u00e4mie \u2013 insbesondere unter RAASi-Therapie. Zum Management der Hyperkali\u00e4mie in deutschen Hausarztpraxen liegen bislang kaum Daten vor.<\/jats:p>\n                  <jats:p>In der retrospektiven Querschnittsstudie WATCH-K wurden 411202 haus\u00e4rztliche PatientInnen mit erh\u00f6htem Hyperkali\u00e4mie-Risiko und dokumentierter chronischer Nierenkrankheit, Herzinsuffizienz, Hypertonie und\/oder Diabetes mellitus eingeschlossen und \u22651 Jahr beobachtet. Bei ihnen wurde die H\u00e4ufigkeit von Serumkaliummessungen, die Pr\u00e4valenz und Diagnosestellung von Hyperkali\u00e4mie sowie deren Therapie mit Kaliumbindern analysiert.<\/jats:p>\n                  <jats:p>In der Gesamtpopulation erhielten 70,8% der PatientInnen eine RAASi-Therapie und bei 35,2% wurde innerhalb eines Jahres mindestens einmal der Serumkaliumspiegel untersucht \u2013 am h\u00e4ufigsten bei CKD \u2013 (44,8%) und HF-PatientInnen (42,8%). Von allen gemessenen PatientInnen zeigten 24,5% (n=35368) hyperkali\u00e4mische Werte, jedoch lag bei nur 2,0% (n=696) eine Diagnose f\u00fcr Hyperkali\u00e4mie vor. Mit Kaliumbindern wurden lediglich 10,9% (n=76) dieser Gruppe behandelt, wobei nur 15,8% (n=12) davon moderne Wirkstoffe wie Natriumzirkoniumcyclosilikat oder Patiromer erhielten.<\/jats:p>\n                  <jats:p>Das Hyperkali\u00e4mie-Management bei RisikopatientInnen sollte in deutschen Hausarztpraxen durch h\u00e4ufigere Kaliumkontrollen und leitliniengerechte Therapien mit Kaliumbindern deutlich optimiert werden, sodass die Prognose der PatientInnengruppe verbessert werden kann. Zudem k\u00f6nnte eine Untersuchung zu den Gr\u00fcnden der zur\u00fcckhaltenden Anwendung empfohlener medikament\u00f6ser Behandlungen aufschlussreich sein.<\/jats:p>","DOI":"10.1055\/a-2823-8256","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:48:05Z","timestamp":1773704885000},"page":"e34-e41","source":"Crossref","is-referenced-by-count":0,"title":["Versorgungssituation von PatientInnen mit Hyperkali\u00e4mie in Deutschland"],"prefix":"10.1055","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-4870","authenticated-orcid":false,"given":"Joerg","family":"Latus","sequence":"additional","affiliation":[{"name":"Robert Bosch Hospital: Robert-Bosch-Krankenhaus GmbH, GERMANY","place":["Stuttgart"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Peschel","sequence":"additional","affiliation":[{"name":"Praxisgemeinschaft Dr. Peschel, Leipzig"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein, Campus L\u00fcbeck, Medizinischen Klinik II f\u00fcr Kardiologie, Angiologie und Intensivmedizin, L\u00fcbeck; Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung (DZHK), Partner site Hamburg\/Kiel\/L\u00fcbeck\/G"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cennet","family":"Handtke","sequence":"additional","affiliation":[{"name":"AstraZeneca GmbH, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Victoria","family":"King","sequence":"additional","affiliation":[{"name":"AstraZeneca GmbH, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingar","family":"Seemann","sequence":"additional","affiliation":[{"name":"AstraZeneca GmbH, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Knebel","sequence":"additional","affiliation":[{"name":"Sana Klinikum Lichtenberg, Klinik f\u00fcr Innere Medizin II, Schwerpunkt Kardiologie, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"KDIGO 2022","year":"2022","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"KDIGO 2024","year":"2024","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease","volume":"10","author":"CP Kovesdy","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"G Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/circheartfailure.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"O Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5114\/aoms.2014.42577","article-title":"Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes","volume":"10","author":"J Khanagavi","year":"2014","journal-title":"Arch Med Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"GMC Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (inkl. Supplement)","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10049-021-00891-z","article-title":"Cardiac arrest under special circumstances","volume":"24","author":"C Lott","year":"2021","journal-title":"Notf Rett Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"KDIGO 2021","year":"2021","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"E Nilsson","year":"2017","journal-title":"Int J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"N Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.008912","article-title":"Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study","volume":"7","author":"RW Thomsen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study","volume":"33","author":"RW Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and\/or Diabetes","volume":"46","author":"AJ Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"ref17","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"M Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"ref18","first-page":"s307","article-title":"The burden of hyperkalemia in patients with cardiovascular and renal disease","volume":"21","author":"JD Dunn","year":"2015","journal-title":"Am J Manag Care"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10741-024-10461-3","article-title":"Hyperkalemia management: a multidisciplinary expert panel\u2019s perspective on the role of new potassium binders","volume":"30","author":"C Fonseca","year":"2025","journal-title":"Heart Failure Reviews"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1053\/j.akdh.2024.08.003","article-title":"Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists","volume":"31","author":"A Rastogi","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.18553\/jmcp.2024.24114","article-title":"Economic burden of recurrent hyperkalemia in patients with chronic kidney disease","volume":"30","author":"G Bakris","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101331","article-title":"Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality","volume":"3","author":"G Bakris","year":"2024","journal-title":"JACC Adv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/ceor.S420217","article-title":"Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study","volume":"15","author":"A Agiro","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/14737167.2023.2161514","article-title":"Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study","volume":"23","author":"CV Pollack","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52994","article-title":"Hyperkalemia: Pharmacotherapies and Clinical Considerations","volume":"16","author":"ES Sinnathamby","year":"2024","journal-title":"Cureus"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1007\/s00392-024-02526-y","article-title":"Entscheidungen zur RAASi-Therapie nach Hyperkali\u00e4mie bei Herzinsuffizienz \u2013 Aufschl\u00fcsse zu Hospitalisierungen und Besuchen von Notaufnahmen aus der ZORA-Studie. DGK Herztage 2024","volume":"113","author":"P Breitbart","year":"2024","journal-title":"Clinical Research in Cardiology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00108-025-01898-1","article-title":"Erh\u00f6htes Hospitalisierungsrisiko bei CKD unter reduzierter RAASi-Therapie nach Hyperkali\u00e4mie: Aufschl\u00fcsse aus der ZORA-Studie. Abstracts zum 131. Kongress der Deutschen Gesellschaft f\u00fcr Innere Medizin e.V","volume":"66","author":"J Latus","year":"2025","journal-title":"Die Innere Medizin"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae083","article-title":"Maintained renin\u2013angiotensin\u2013aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study","volume":"17","author":"A Rastogi","year":"2024","journal-title":"Clinical Kidney Journal"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"J Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure","volume":"85","author":"MN Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s11606-024-09107-9","article-title":"Are Newer Potassium Binding Agents Truly Better? Rethinking Sodium Polystyrene Sulfate and Emerging Therapies for Hyperkalemia","volume":"40","author":"M Mehta","year":"2025","journal-title":"Journal of General Internal Medicine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12325-022-02420-x.","article-title":"The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings","volume":"40","author":"JF Neuenschwander","year":"2023","journal-title":"Advances in Therapy"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2823-8256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:35:22Z","timestamp":1779143722000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2823-8256"}},"subtitle":["Erkenntnisse zu Monitoring, Diagnose und Behandlung erh\u00f6hter Kaliumwerte"],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,5,18]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2823-8256","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}